Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era?

類似資料

• Update on third-generation EGFR tyrosine kinase inhibitors
  著者:: Gray, Jhanelle, 等
  出版事項: (2014)
• Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond
  著者:: Ou, Sai-Hong Ignatius
  出版事項: (2011)
• Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line
  著者:: Sullivan, Ivana, 等
  出版事項: (2017)
• Phase II trial of dacomitinib, a pan–human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification
  著者:: Sepúlveda-Sánchez, Juan Manuel, 等
  出版事項: (2017)
• Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
  著者:: Suda, Kenichi, 等
  出版事項: (2021)